Diuretic Use in Hemodialysis Patients With Residual Renal Function (DIURESED)

Diuretic Use in Hemodialysis Patients With Residual Renal Function: a Proof of Concept Study

This pilot trial will evaluate the use of diuretic medications (furosemide and chlorthalidone) in participants on dialysis to see if these medications work to preserve existing kidney function, increase urine output, and reduce weight gain between dialysis treatments. Diuretics, which are sometimes called water pills, help the body to get rid of salt (sodium) and water. There are currently no guidelines for the use of diuretic medications in dialysis patients, including the type to use, or how much to use.

Study Overview

• Status: Terminated
• Conditions: End Stage Renal Disease on Dialysis
• Intervention / Treatment: Drug: Furosemide; Drug: Chlorthalidone

Detailed Description

Fluid overload, or extracellular fluid volume expansion, in patients on hemodialysis is an important predictor of mortality. It is associated with hypertension and left ventricular hypertrophy - both risk factors for cardiovascular disease. In the United States, 80% of patients receiving hemodialysis have hypertension and 40% of patients on hemodialysis die from cardiovascular disease. The pathophysiology of hypertension in these patients is multifactorial, however, combined excess fluid and sodium is a key contributor.

While ultrafiltration (removal of fluid through dialysis) is important in managing fluid overload, fluid removed by hemodialysis is a non-physiological process which imposes hemodynamic stress on the cardiovascular system in uremic patients. This system is already maladaptive as a result of decreased baroreceptor sensitivity and increased vascular stiffness, leading to higher risk of hemodynamic instability when fluid is removed from the intravascular compartment. In patients who are anuric, restriction of fluid and sodium intake and ultrafiltration are the only options for volume control. In patients who continue to produce urine, however, optimizing the amount of urine produced could improve fluid overload and decrease cardiovascular stress.

Previous studies have shown that patients on hemodialysis who have residual renal function have better volume and sodium control. Higher residual renal function and higher urine output lead to a lower interdialytic weight gain in patients receiving hemodialysis; each of these factors have been associated with lower mortality. One intervention that may increase or help maintain residual renal function and increase urine output and therefore reduce interdialytic weight gain is diuretic therapy, which promotes the excretion of sodium and water by the native kidneys. Questions remain regarding the dose-response of the drug furosemide, about the utility of adding the drug chlorthalidone, and their clinical affects.

The main objective of this study is to determine the effects of starting, and escalating doses of diuretic medications (furosemide +/- chlorthalidone) on 24-hour urine output (volume) over a five-week period in patients on hemodialysis who produce >200cc per day of urine.

Secondary objectives are:

1. To evaluate the effect of diuretic medications on residual renal function
2. To evaluate the effect of different doses of diuretics on interdialytic weight gain, ultrafiltration rates and intradialytic hypotension
3. To examine the effect of diuretics on patient reported outcomes
4. To evaluate adverse effects of different doses of diuretics
5. To measure serum furosemide levels in this patient population

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Phase 4

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 2B7
      • University of Alberta

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adult patients (age 18 years or older), who are within their first 12 months of chronic (expected to need dialysis for at least 6 months), in-centre hemodialysis therapy, and
• Residual renal function defined as 24-hour urine volume >200cc, and
• Life expectancy of at least 6 months, and
• Participants must be able to understand the consent process and be able to sign a consent form or have a substitute decision maker who is able to understand and sign consent on their behalf. In the case of non-English speaking participants, a translator service will be used to provide study information and obtain consent.

Exclusion Criteria:

• Unable to complete baseline urine collection
• Documented allergy or adverse reaction to furosemide or chlorthalidone.
• Unable to take oral medications
• Patients expecting to change modality (peritoneal dialysis, home dialysis) or to receive a renal transplant in the next 6 weeks
• History of hypokalemia (<3.0 mmol/L), hypomagnesemia (<0.6mmol/L), or hypocalcaemia (<1.9mmol/L) in preceding 2 weeks.
• Already participating in another study and one of the studies could interfere with the other study
• Use of loop, or thiazide diuretic medications in the last week (if a patient is on chronic diuretics, they would need to be discontinued for 1 week before starting the trial)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Diuretic Therapy

Drug: Furosemide; Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.; Drug: Chlorthalidone; Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 1
Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 2
Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 3
Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 4
Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 5
Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 1
Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 2
Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 3
Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 4
Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 5

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Interdialytic weight gain	Patient weight measured in kilograms	Week 1
Interdialytic weight gain	Patient weight measured in kilograms	Week 2
Interdialytic weight gain	Patient weight measured in kilograms	Week 3
Interdialytic weight gain	Patient weight measured in kilograms	Week 4
Interdialytic weight gain	Patient weight measured in kilograms	Week 5
Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 1
Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 2
Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 3
Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 4
Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 5
Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 1
Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 2
Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 3
Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 4
Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 5
Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 1
Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 2
Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 3
Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 4
Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 5
Urine furosemide levels	Urine furosemide levels from weekly urine samples	Week 3
Urine furosemide levels	Urine furosemide levels from weekly urine samples	Week 4
Urine furosemide levels	Urine furosemide levels from weekly urine samples	Week 5

Collaborators and Investigators

• Sponsor: University of Alberta
• Investigators: Principal Investigator: Branko Braam, MD/Ph.D., University of Alberta

Study record dates

Study Major Dates

• Study Start (Actual): May 29, 2023
• Primary Completion (Actual): February 21, 2025
• Study Completion (Actual): February 21, 2025

Study Registration Dates

• First Submitted: June 13, 2023
• First Submitted That Met QC Criteria: June 13, 2023
• First Posted (Actual): June 22, 2023

Study Record Updates

• Last Update Posted (Actual): May 8, 2026
• Last Update Submitted That Met QC Criteria: May 4, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Pathologic Processes; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Chronic Disease; Disease Attributes; Renal Insufficiency; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Sulfur Compounds; Organic Chemicals; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Cyclic; Hydrocarbons, Aromatic; Amides; Aniline Compounds; Amines; Benzene Derivatives; Phthalimides; Isoindoles; Benzenesulfonamides; Sulfonamides; Sulfanilamides; Sulfones; Ketones; Benzophenones; Imides; Furosemide; Chlorthalidone
• Other Study ID Numbers: Pro00119451

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No